Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

44.16 -0.43 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 398,881
Open 43.82
Bid (Size) 42.41 (1)
Ask (Size) 45.85 (1)
Prev. Close 44.59
Today's Range 43.82 - 45.61
52wk Range 27.36 - 49.56
Shares Outstanding 59,493,704
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire

Performance

YTD
+18.49%
+18.49%
1 Month
+9.61%
+9.61%
3 Month
+30.34%
+30.34%
6 Month
+2.65%
+2.65%
1 Year
+0.59%
+0.59%

More News

Read More
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Expert Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics's Return On Capital Employed Insights
Via Benzinga
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
Via Benzinga
Sage Therapeutics: Q2 Earnings Insights
Via Benzinga
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Mental Health Claims up 75% Since 2019
Via PressReach
Mental Health Claims up 75% Since 2019
Via FinancialNewsMedia
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Via Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.